2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow imdevimab: new trials by email Literature Review of imdevimab trials Research Report on imdevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults casirivimab+imdevimab, Placebo - Immunocompromised | Phase 3 | Terminated | Regeneron Pharmaceuticals | 66 | 2021-10-25 | 2025-10-20 |
| Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 casirivimab+imdevimab combination therapy - COVID-19 | Phase 3 | Terminated | Regeneron Pharmaceuticals | 10078 | 2020-06-16 | 2023-12-21 |
COVID-19 (2) · Coronavirus Infections (1)
Mexico (2) · United States (2) · Romania (1)
PMID 33332778, PMID 34473343, PMID 34587383, PMID 35713300, PMID 37079569, PMID 38102791, PMID 38961047, PMID 39384241